|
Chronic Lymphocytic Leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Linkage of the mir-15a/16-1 complex and the development of B-LPD in this spontaneous mouse model suggest that the altered expression of the mir-15a/16-1 is the molecular lesion in CLL.
|
17351108 |
2007 |
|
Diffuse Large B-Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The frequency of diffuse large B cell lymphoma (DLBCL) and positive rate of Epstein-Barr virus (EBV) in RA-LPD was significantly higher than in sporadic LPD (57.9% vs 42.7%, 27.6% vs 9.9%, respectively).
|
17117491 |
2007 |
|
Malignant neoplasm of breast
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Previous studies from our group have demonstrated the antitumor efficacy of systemically administered, folate-targeted, lipid-protamine-DNA complexes (LPD-PEG-Folate) against breast cancer using an immunodeficient xenogenic murine model.
|
14671672 |
2004 |
|
Epstein-Barr Virus Infections
|
0.020 |
Biomarker
|
group |
BEFREE |
These findings suggest that 1) EBV infection in patients with PT-LPDs occurs with a w- or del-LMP1-type EBV isolate and does not change once a patient acquires the virus and 2) the infection is an early event in the development of PT-LPDs and transformation is induced regardless of the type of LMP1.
|
9284829 |
1997 |
|
Lymphoma
|
0.020 |
Biomarker
|
group |
BEFREE |
To further investigate the potential relationship of del-LMP-1 to EBV-LPDs associated with immunosuppression or immunodeficiency, we studied 39 EBV-associated lymphoproliferations (10 benign, 29 malignant) from four distinct clinical settings: posttransplant (4 malignant, 1 reactive); HIV+ (18 malignant, 2 reactive); nonimmunodeficiency malignant lymphoma (ML) (7 cases); and sporadic EBV infection with lymphoid hyperplasia (7 cases).
|
8704180 |
1996 |
|
Epstein-Barr Virus Infections
|
0.020 |
Biomarker
|
group |
BEFREE |
To further investigate the potential relationship of del-LMP-1 to EBV-LPDs associated with immunosuppression or immunodeficiency, we studied 39 EBV-associated lymphoproliferations (10 benign, 29 malignant) from four distinct clinical settings: posttransplant (4 malignant, 1 reactive); HIV+ (18 malignant, 2 reactive); nonimmunodeficiency malignant lymphoma (ML) (7 cases); and sporadic EBV infection with lymphoid hyperplasia (7 cases).
|
8704180 |
1996 |
|
Immune System Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
106 primary ITP patients (16 with newly-diagnosed ITP, 16 with persistent ITP and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated.
|
31840311 |
2020 |
|
Glioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The lower fatty acyl pool may be mediated by the lower protein expression levels of long-chain acyl-CoA synthetase 1 (ACSL1), ACSL4, and very long-chain acyl-CoA synthetase 3 (ACSVL3) in IDH1 mutant glioma.
|
30596429 |
2019 |
|
Intestinal Obstruction
|
0.010 |
Biomarker
|
disease |
BEFREE |
The diagnosis of T-LPD should be made cautiously in case with progressing symptoms such as intestinal obstruction.
|
31027102 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that testing for CD13 expression in routine flow cytometry panels could help to discriminate WM/LPL from other B-LPD.
|
30198568 |
2019 |
|
Systemic Scleroderma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<b>Results:</b> VICM and BGM levels were increased in early compared with late dSSc (<i>p</i>< =0.023).
|
30457356 |
2019 |
|
Malignant lymphoma - lymphoplasmacytic
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that testing for CD13 expression in routine flow cytometry panels could help to discriminate WM/LPL from other B-LPD.
|
30198568 |
2019 |
|
Aggressive Non-Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Early detection of high-grade transformation of T-LPD or the coexistence of aggressive lymphoma is essential for the patient.
|
31027102 |
2019 |
|
Malignant Neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The Danish "Suspicious" group was allocated to the BG I, II, III, IV, V and VI with a malignancy risk of 36.4%, 13.3%, 17.2%, 16.1%, 55.3% and 88.2%, respectively.
|
29510805 |
2018 |
|
Hodgkin Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Forty-three patients showed regression (Reg group), with high rates of Hodgkin lymphoma (HL) and LPD (90 and 88%, respectively).
|
28877615 |
2018 |
|
Long QT Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
The disagreement between BGM and MM <15 ms in all, in controls, and in LQTS was respectively 57%, 63% and 54%.
|
29887480 |
2018 |
|
Parkinson Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Multivariate regression analyses indicated that a younger age at disease onset (OR = 0.520, 95%CI = 0.295-0.919, p = 0.024), lower annual change in UPDRS III score (OR = 0.009, 95%CI = 0.001-0.246, p = 0.005) and lower 'cardiovascular' score (OR = 0.552, 95%CI = 0.319-0.955, p = 0.034) were associated with 20-year survival, while UPDRS III (β = 0.320, p < 0.001) and NMSS (β = 0.549, p < 0.001) scores were associated with the PD Questionnaire 39 score in LPD.
|
29447582 |
2018 |
|
High Grade Lymphoma (neoplasm)
|
0.010 |
Biomarker
|
disease |
BEFREE |
We present an unusual case of indolent T-cell lymphoproliferative disorder with aberrant CD20 expression, Recognition of this unusual immunophenotype of indolent T-cell LPD of GI helps to eschew misdiagnosis of B-cell and other high grade lymphomas and inappropriate aggressive treatment.
|
30342536 |
2018 |
|
Adult Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Forty-three patients showed regression (Reg group), with high rates of Hodgkin lymphoma (HL) and LPD (90 and 88%, respectively).
|
28877615 |
2018 |
|
Childhood Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Forty-three patients showed regression (Reg group), with high rates of Hodgkin lymphoma (HL) and LPD (90 and 88%, respectively).
|
28877615 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The Danish "Suspicious" group was allocated to the BG I, II, III, IV, V and VI with a malignancy risk of 36.4%, 13.3%, 17.2%, 16.1%, 55.3% and 88.2%, respectively.
|
29510805 |
2018 |
|
Chronic Kidney Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Furthermore, KA supplementation reversed the elevation in p66Shc and FoxO3a expression in the muscles of CKD + LPD rats.
|
29855350 |
2018 |
|
Hydroa vacciniforme-like lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders (EBV<sup>+</sup> T/NK LPD) encompass a heterogeneous group of disorders, including chronic active Epstein-Barr virus infection (CAEBV), Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH), systemic EBV<sup>+</sup> T-cell lymphoma of childhood and hydroa vacciniforme-like lymphoproliferative disorder (HVLPD) and so on, predominantly affecting children and young adults with high mortality.
|
30356785 |
2018 |
|
PARKINSON DISEASE, LATE-ONSET
|
0.010 |
Biomarker
|
disease |
BEFREE |
Background The number of Parkinson's disease (PD) patients with disease duration of more than 20 years (long disease duration PD, LPD) is on the rise.
|
29447582 |
2018 |
|
Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form
|
0.010 |
Biomarker
|
disease |
BEFREE |
Primary acute or chronic active Epstein-Barr virus infection triggers EBV+ T-LPD's onset and the disease involves clonal proliferation of infected T-cells with activated cytotoxic phenotype.
|
30519236 |
2018 |